LIFE News and Press, aTyr Pharma Inc. From 09/12/22

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...

SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Ashlee Dunston, Di...

SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chi...

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday, Sep...

aTyr Pharma ( NASDAQ: LIFE ) stock rose ~15% on Aug. 16 following the company's Q2 results a day ago, wherein net loss per share came in line with analysts' estimates . Q2 net loss attributable to aTyr Pharma was -$12.42M, compared to -$10.39M in Q2 2021. R...

aTyr Pharma, Inc. (LIFE) Q2 2022 Earnings Conference Call August 15, 2022 05:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations and Corporate Communications Sanjay Shukla - President & Chief Executive Officer Leslie Nangle - Vice Pres...

aTyr Pharma press release ( NASDAQ: LIFE ): Q2 GAAP EPS of -$0.44 in-line. Cash, restricted cash, cash equivalents and investments as of June 30, 2022, were $89.3 million. In May 2022, announced plans to initiate the global pivotal EFZO-FIT ™ study, a global...

First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash ...

The shares of clinical-stage biotech aTyr Pharma, Inc. ( NASDAQ: LIFE ) jumped ~7% in the pre-market Thursday after the company announced that the FDA issued Fast Track designation for its lead candidate efzofitimod for immune-mediated disease, pulmonary sarcoidosis. An im...

SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced t...